TB-500 (Thymosin Beta-4)

At a glance

Standard Protocol

Alternative: Daily Micro-Dosing

Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (G-Actin; TGF-beta); route Subcutaneous; timing Anytime. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. TB-500 is commonly treated online as if every thymosin beta-4 paper applies to it. That is too loose: TB-500 is marketed as a fragment/related synthetic peptide, so protocol logic should stay conservative and avoid claiming full-protein thymosin beta-4 dosing proof.

• Lethargy and fatigue immediately following injection: the most commonly reported adverse effect; estimated 15-25% of users anecdotally; typically within 1-2 hours post-injection; resolves within the same day; related to the acute inflammatory modulation signal.
• Head rush or vasodilation sensation: warmth or blood rushing to the head within minutes of injection; reported in a minority of users; more common with macro-dose twice-weekly protocols than with daily micro-dosing; caused by angiogenic/vasodilatory mechanism; the daily micro-dosing protocol was specifically developed to mitigate this effect.
• Temporary dizziness: associated with the vasodilation response; transient.
• Injection site irritation: redness, minor swelling at subcutaneous injection site; estimated 20-30% of users anecdotally; normal tissue response.
• Headache: rare; less than 10% anecdotally; transient; likely vasodilation-mediated.
• Nausea: rare; less than 5% anecdotally; usually dose-related; less common than with BPC-157.
• Theoretical cancer cell migration risk: the most significant theoretical adverse effect; actin-mediated cell motility enhancement does not distinguish between healthy and malignant cells; this is the mechanistic basis for the cancer contraindication.
• Theoretical angiogenesis in pathological contexts: new vessel formation that supports wound healing in normal tissue could support tumor vascularization in oncological contexts.
• No significant hormonal side effects: unlike GH axis compounds, TB-500 does not affect the endocrine system, does not elevate cortisol or prolactin, and does not suppress natural hormonal production.
• No receptor desensitization: no documented downregulation of target pathways with standard cycle lengths; efficacy does not attenuate within a single cycle.

• Active cancer or high cancer risk: TB-500 promotes cell migration and angiogenesis via actin-mediated cellular motility and TGF-beta modulation; these mechanisms that accelerate healing in normal tissue also accelerate tumor cell migration, invasion, and neovascularization in malignant tissue.
• History of malignancy: the pro-migratory and pro-angiogenic mechanisms present theoretical risk of stimulating dormant or residual tumor cells; assess with care.
• Active cancer treatment (chemotherapy or radiation): TB-500's pro-migratory cell effects may theoretically interfere with cytotoxic therapy mechanisms by protecting cancer cells from treatment-induced damage.
• Pregnancy: no safety data; avoid.
• Breastfeeding: no safety data; avoid.
• Known hypersensitivity to Thymosin Beta-4, TB-500, or peptide excipients.
• Anticoagulant or antiplatelet therapy: potential additive effect via actin-mediated platelet function modulation; theoretical, but warrants monitoring.
• Proliferative vascular disorders: subjects with pathological neovascularization or arteriovenous malformations.
• Active autoimmune disorders: TB-500's immune modulatory properties (particularly TGF-beta modulation) carry theoretical risk of unpredictable immune activation in autoimmune-susceptible subjects.
• Pediatric use: no safety or efficacy data established.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• https://pubmed.ncbi.nlm.nih.gov/?term=TB-500+%28Thymosin+Beta-4%29